查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1952811

镰状细胞疾病治疗市场按治疗类型、患者年龄层、给药方式、疾病类型和最终用户划分－全球预测，2026-2032年

Sickle Cell Disease Treatment Market by Treatment Type, Patient Age Group, Drug Administration Method, Disease Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，镰状细胞疾病治疗市场价值将达到 19.9 亿美元，到 2026 年将成长至 21 亿美元，到 2032 年将达到 31.4 亿美元，年复合成长率为 6.75%。

关键市场统计数据
基准年 2025 19.9亿美元
预计年份：2026年 21亿美元
预测年份 2032 31.4亿美元
复合年增长率 (%) 6.75%

一种针对现代镰状细胞疾病护理环境的策略方法，将临床进展与对医疗服务提供者、支付者和製造商的实际意义联繫起来。

镰状细胞疾病 (SCD) 处于血液学、遗传学和健康差异等关键领域的交汇点，临床、研究和商业相关人员需要清晰的策略洞察，才能驾驭加速发展的治疗创新。本文透过整体情况目前的标准治疗方案与新兴治疗方法，并重点阐述基因编辑、细胞疗法和标靶药物疗法的进展如何改变患者的治疗路径，从而全面展现了治疗格局。透过整合临床试验结果、监管里程碑和不断变化的医疗服务模式，我们阐明了渐进式改善与变革性潜力之间的交集。

医学遗传学、监管加速和医疗保健服务领域的融合突破将如何重塑镰状细胞疾病的长期治疗策略

随着技术、监管和临床因素的融合，镰状细胞疾病治疗格局正在经历变革性变化。基因医学和细胞工程的进步已将基因治疗平台从概念阶段推进到具体的临床项目，重新定义了缓解疾病和慢性管理。同时，药物治疗的逐步改进，包括新型製剂和优化的支持治疗通讯协定，在许多临床环境中提高了症状控制率并减少了急诊治疗的使用。

评估美国关税调整至 2025 年对供应链、製造策略和临床准入途径的营运和商业影响

到2025年，美国关税政策变化的累积影响正在全球医疗保健供应链中造成显着的摩擦，尤其对镰状细胞疾病治疗所需的治疗方法和辅助用品影响尤为显着。进口生物试剂、基因和细胞疗法专用生产设备以及某些输血和血液分离术医疗设备均面临更高的进口关税和合规成本，迫使相关人员重新评估筹资策略和供应链冗余。因此，一些製造商正在加快在国内或邻近地区的生产投资，以降低贸易相关成本波动的风险，并确保高度复杂产品的持续供应。

根据治疗方法、人群、给药途径、疾病亚型和医疗保健环境，制定具有高解析度细分目标市场的精准打入市场策略

有效的细分能清楚展现镰状细胞疾病治疗方法和医疗环境的多样性，进而为产品开发和服务提供更精准的策略。在考虑治疗类型时，必须区分「输血通讯协定」（包括用于危机管理的急性输血和用于长期预防併发症的慢性输血）和「骨髓移植途径」（其中异基因移植具有根治性的潜力）。后者与自体移植（使用患者自身细胞）有所不同。按药物治疗进行细分，可以进一步区分诸如Endari等L-谷氨酰胺製剂、旨在永久性基因矫正的新兴基因治疗方法，以及羟基脲等已确立的药物（羟基脲仍然是许多患者的基础治疗方法）。

区域趋势导緻美洲、欧洲、中东和非洲以及亚太地区的医疗保健生态系统在采用率、基础设施投资和进入策略方面存在差异。

区域趋势对镰状细胞疾病治疗方法的采纳、交付和商业化产生了显着影响，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。在美洲，完善的新生儿筛检计画、专业的三级医疗中心和集中化的病患支援网络营造了有利于早期采用先进治疗方法和进行专业临床试验的环境。同时，医保报销的讨论仍围绕着长期价值和可负担性。而在欧洲、中东和非洲，情况则更为复杂，有些国家实现了监管协调，而有些国家则面临基础设施的限制。这将导致不同地区的药物采纳时间表存在差异，并需要製定针对性的市场准入策略。

由製药公司、生物技术创新者、临床中心和专业服务供应商组成的协作生态系统如何重塑商业化和证据生成策略

在镰状细胞疾病领域，各公司之间的竞争与合作行为呈现出广泛的频谱，涵盖了从老牌製药企业到小规模的生物技术公司和专业服务供应商。现有製药公司继续利用其强大的商业能力、现有的医疗保险支付关係和分销网络来支持药物和辅助治疗产品的销售。小规模的生物技术和基因疗法开发商则致力于推进创新根治性，依靠与学术机构的策略伙伴关係、许可协议和临床合作来加速研发进程并获取特定临床试验族群。

为经营团队提供切实可行的操作建议，以确保供应的确定性，使证据与支付方的需求保持一致，并加快公平获得新的镰状细胞疾病治疗。

行业领导者应优先考虑一系列切实可行的倡议，将科学进步转化为可及的治疗方法和永续的商业项目。首先，需要投资可扩展的生产製造和多元化的供应链，以确保高复杂度疗法的稳定供应，同时降低贸易和关税风险。其次，应儘早纳入卫生经济学和结果研究，使临床开发计划与支付方的证据要求保持一致，从而加强基于价值的合约和长期报销。

采用严谨的混合方法调查方法，结合专家访谈、系统性文献回顾和三角验证技术，以经验证的证据检验策略性结论。

本分析的调查方法结合了第一手资料和第二手资料，以确保研究的严谨性、透明度和可重复性。第一手资料包括对血液科医生、移植医生、临床试验研究人员、医院采购人员和支付方代表进行结构化访谈，以收集关于临床实践、采购限制和证据要求的第一手观点。此外，还举办了专家圆桌会议和咨询会议，以深入了解输血、骨髓移植和新兴基因疗法实施过程中面临的营运挑战。

整合临床、营运和政策方面的必要因素，以製定实现镰状细胞疾病治疗药物持续获益和永续商业化的路径

总之，镰状细胞疾病治疗的方向正从以症状为中心的治疗转向以缓解疾病为目标的治疗方法，这主要得益于基因和细胞疗法、优化药物治疗以及支持性治疗的进步。这种转变既带来了机会，也带来了责任：机会在于实现变革性的患者疗效，责任在于确保公平的治疗机会、维护安全监管以及建立复杂治疗所需的必要基础设施。策略上的成功取决于相关人员在临床、商业和政策领域合作的能力，同时始终坚持以病人为中心的原则。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章镰状细胞贫血症治疗市场（依治疗方法）

  • 输血疗法
    • 急性输血
    • 慢性输血
  • 骨髓移植
    • 同种异体移植
    • 自体移植
  • 药物治疗
    • Endari（L-麸酰胺酸）治疗
    • 基因治疗
    • 羟基脲治疗

第九章 依患者年龄层镰状细胞疾病治疗市场

  • 成人版
  • 儿童

第十章 以药物传递方式镰状细胞疾病治疗市场

  • 静脉注射
  • 口服

第十一章镰状细胞疾病治疗市场（依疾病类型划分）

  • 血红素S-C症（HbSC）
  • 镰状细胞贫血症（HbSS）

第十二章镰状细胞疾病治疗市场（以最终用户划分）

  • 诊所
  • 医院
    • 私立医院
    • 公立医院
  • 研究所

第十三章镰状细胞疾病治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章镰状细胞疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国镰状细胞疾病治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国镰状细胞疾病治疗市场

第十七章：中国镰状细胞疾病治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akums Drugs and Pharmaceuticals Ltd.
  • Beam Therapeutics, Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • F. Hoffmann-La Roche AG
  • GlycoMimetics, Inc.
  • Intellia Therapeutics, Inc.
  • Medunik USA
  • Novartis AG
  • Protagonist Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Vertex Pharmaceuticals, Inc.
  • Vor Biopharma, Inc.
Product Code: MRR-B570E7E0C82D

The Sickle Cell Disease Treatment Market was valued at USD 1.99 billion in 2025 and is projected to grow to USD 2.10 billion in 2026, with a CAGR of 6.75%, reaching USD 3.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.99 billion
Estimated Year [2026] USD 2.10 billion
Forecast Year [2032] USD 3.14 billion
CAGR (%) 6.75%

A strategic orientation to the contemporary sickle cell therapeutic landscape linking clinical advances with practical implications for providers, payers, and manufacturers

Sickle cell disease (SCD) occupies a critical intersection of hematology, genetics, and health equity, and stakeholders across clinical, research, and commercial settings require clear, strategic intelligence to navigate accelerating therapeutic innovation. This introduction frames the therapeutic landscape by situating current standard-of-care practices alongside emergent modalities, highlighting how advances in gene editing, cell therapy, and targeted pharmacotherapies are reshaping patient pathways. By synthesizing clinical trial outcomes, regulatory milestones, and shifting care delivery models, the report contextualizes where incremental improvements meet transformative potential.

The intent here is to provide readers with a concise but rigorous orientation that clarifies key clinical terminologies, typical patient journeys, and the stakeholder incentives that influence adoption. Emerging therapies are discussed in relation to established interventions to help readers appreciate comparative value, safety considerations, and operational implications for administering care. This orientation sets the stage for subsequent sections by linking scientific developments to practical considerations for payers, providers, manufacturers, and patient advocates.

Transitioning from clinical foundations to strategic implications, the narrative underscores the importance of multidisciplinary coordination, capacity building in specialized centers, and supply chain resilience as essential enablers of broad access. The conclusion of this opening segment emphasizes that strategic foresight grounded in robust evidence will be crucial for stakeholders seeking to maximize patient benefit while navigating an increasingly complex commercial environment.

How converging breakthroughs in genetic medicine, regulatory acceleration, and care delivery are reshaping long-term therapeutic strategies for sickle cell disease

The sickle cell therapeutic landscape is experiencing transformative shifts driven by converging technological, regulatory, and clinical forces. Advances in genetic medicine and cell engineering have elevated gene therapy platforms from conceptual promise to tangible clinical programs, prompting a reassessment of long-term disease modification versus chronic management. Concurrently, incremental improvements in pharmacotherapy, including novel formulations and optimized supportive care protocols, are improving symptom control and reducing acute care utilization in many clinical contexts.

Regulatory pathways have adapted to accommodate accelerated development models for rare and severe conditions, which in turn affects development timelines and commercial entry strategies. Reimbursement stakeholders are increasingly focused on long-term value propositions and outcomes-based contracting, creating pressure for manufacturers to develop clear evidence-generation plans that span registries, real-world studies, and long-term follow-up. At the same time, improvements in diagnostic screening and newborn programs are influencing earlier detection and care planning, particularly in regions with established public health infrastructures.

Operationally, the rise of complex therapies has sharpened attention on manufacturing scale-up, cold-chain logistics, and specialized care delivery sites capable of performing cellular therapies or managing intensive transfusion programs. These shifts collectively reorient the landscape from episodic symptomatic care toward integrated care models that blend curative intent with sustainable chronic disease management, requiring new partnerships across clinical, commercial, and policy domains.

Assessing the operational and commercial consequences of United States tariff adjustments through 2025 on supply chains, manufacturing strategy, and clinical access pathways

The cumulative impact of tariff policy changes implemented in the United States through 2025 has introduced measurable friction across global healthcare supply chains, with specific implications for therapies and ancillary supplies used in sickle cell disease management. Imported biologic reagents, specialized manufacturing equipment for gene and cell therapies, and certain medical devices for transfusion and apheresis have been subject to elevated import duties and compliance costs, prompting stakeholders to re-evaluate sourcing strategies and supply chain redundancy. As a result, some manufacturers have accelerated onshore or nearshore manufacturing investments to mitigate exposure to trade-related cost volatility and to ensure continuity of supply for high-complexity products.

In parallel, clinical sites that rely on imported consumables for bone marrow transplant procedures and intravenous administration have encountered increased procurement lead times and higher landed costs, which in turn affect operational budgets and scheduling flexibility. Payers and health systems have responded by scrutinizing procurement contracts and by favoring vendors that demonstrate secure supply chains and localized production capabilities. Additionally, tariff-driven cost pressures have encouraged manufacturers to pursue strategic partnerships with contract manufacturing organizations and to explore technology transfer arrangements that reduce cross-border logistics complexity.

While tariffs have not uniformly shifted clinical decision-making, the downstream commercial and operational consequences are clear: stakeholders must incorporate trade policy risk into procurement planning, capital investment decisions, and pricing strategies. Those entities that proactively diversify manufacturing footprints and strengthen distributor relationships are better positioned to maintain service continuity and to protect access for patients dependent on complex therapies and supportive care.

High-resolution segmentation that aligns treatment modalities, patient demographics, administration routes, disease subtypes, and care settings to inform targeted go-to-market strategies

Meaningful segmentation reveals the heterogeneity of therapeutic approaches and care settings encountered in sickle cell disease, enabling more precise strategy development for product development and service delivery. When considering treatment types, it is essential to distinguish between blood transfusion protocols-which encompass both acute transfusion for crisis management and chronic transfusion for long-term prevention of complications-and bone marrow transplant pathways, where allogeneic transplant offers curative potential distinct from autologous approaches that leverage patient-derived cells. Pharmacotherapy segmentation further differentiates between therapies such as L-glutamine formulations like Endari, the expanding field of gene therapy modalities aiming at durable genetic correction, and long-established agents like hydroxyurea that continue to serve as backbone treatments for many patients.

Patient demographics introduce another layer of differentiation: adult and pediatric populations display distinct clinical trajectories, tolerability profiles, and care coordination needs, necessitating tailored evidence generation and dosing strategies. Administration routes are material to adoption and adherence, with intravenous therapies imposing different site-of-care requirements compared with oral regimens that enable outpatient and community-based management. Disease subtype remains a pivotal stratifier, as clinical manifestations and complication risk vary between Hemoglobin SC disease (HbSC) and sickle cell anemia (HbSS), thereby influencing therapeutic prioritization.

End-user settings provide the final axis of segmentation insight: clinics, hospitals-encompassing both private and public institutions-and research institutions each present unique operational constraints and purchasing behaviors. Together, these intersecting segmentation dimensions illuminate where clinical benefit, operational feasibility, and commercial potential converge, informing launch sequencing, pricing strategies, and stakeholder engagement plans.

Regional dynamics driving differential adoption, infrastructure investment, and access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific healthcare ecosystems

Regional dynamics exert a strong influence on the uptake, delivery, and commercialization of sickle cell therapies, with distinctive patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established newborn screening programs, specialized tertiary centers, and concentrated patient advocacy networks create an environment where advanced therapies and specialized clinical trials can achieve early traction, while reimbursement debates continue to center on long-term value and affordability. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape in which regulatory harmonization in some countries coexists with constrained infrastructure in others, leading to variable adoption timelines and a need for regionally tailored access strategies.

The Asia-Pacific region offers a mix of rapidly developing healthcare markets and mature systems that prioritize domestic capacity building for advanced biologics and cellular therapies. In many countries across Asia-Pacific, investments in manufacturing and clinical research are accelerating, but access remains shaped by differing regulatory frameworks, variable public health coverage, and localized cost sensitivities. In the Middle East and parts of Africa, the concentration of specialized centers in urban hubs can facilitate high-complexity care for select patient cohorts, yet broader access requires targeted capacity building and international collaboration.

Across all regions, cross-border partnerships, knowledge transfer, and investments in local clinical infrastructure are recurring themes. Stakeholders should calibrate regional strategies to account for differences in payer models, clinical capacity, population screening practices, and supply chain complexity to optimize patient access and commercial sustainability.

How collaborative ecosystems of pharmaceutical firms, biotech innovators, clinical centers, and specialized service providers are reshaping commercialization and evidence generation strategies

The competitive and collaborative behaviors of companies operating in the sickle cell space reflect a spectrum that ranges from legacy pharmaceutical manufacturers to small biotechnology firms and specialized service providers. Established pharmaceutical companies continue to leverage broad commercial capabilities, existing payer relationships, and distribution networks to support pharmacotherapies and supportive care products. Smaller biotech and gene therapy developers are advancing novel curative approaches, often relying on strategic partnerships, licensing agreements, and clinical collaborations with academic centers to accelerate development and to access specialized clinical trial populations.

Contract manufacturing organizations, supply chain specialists, and cell therapy service providers have become indispensable partners as companies scale complex biologic and gene-modifying products. Research institutions and hospital systems play dual roles as clinical investigators and early adopters, collaborating with industry to generate real-world evidence and to refine patient selection and care pathways. Across this ecosystem, deal activity frequently centers on technology transfer, co-development arrangements, and capacity-building investments designed to shorten time-to-patient and to secure manufacturing throughput.

From a strategic perspective, companies that invest in integrated evidence-generation programs, demonstrate supply chain resilience, and form credible partnerships with clinical networks are more likely to achieve sustainable adoption. Similarly, organizations that align commercial planning with payer evidence needs and that design pragmatic long-term follow-up studies will reduce barriers to reimbursement and accelerate patient access.

Operationally pragmatic recommendations for executives to secure supply reliability, align evidence with payer needs, and accelerate equitable access to novel sickle cell therapies

Industry leaders should prioritize a set of actionable initiatives that translate scientific progress into accessible care and sustainable commercial programs. First, invest in scalable manufacturing and diversified supply chains to mitigate trade and tariff vulnerabilities while ensuring consistent product availability for high-complexity therapies. Second, align clinical development plans with payer evidence requirements by embedding health economics and outcomes research from early phases, thereby strengthening the case for value-based contracting and long-term coverage.

Third, cultivate multi-stakeholder partnerships that bridge industry, clinical centers, and patient advocacy groups to co-design patient-centric care pathways and to expedite pragmatic trials and registries. Fourth, develop differentiated access models that account for patient age groups, administration routes, and regional infrastructure constraints, ensuring that both pediatric and adult populations receive appropriately tailored treatment options. Fifth, prepare robust launch readiness programs that include training for specialized care teams, site accreditation support, and logistics planning for intravenous and cellular therapies.

Finally, adopt modular commercial strategies that accommodate variability across disease subtypes and end-user settings, and invest in long-term safety and effectiveness surveillance to reinforce confidence among clinicians and payers. By executing on these priorities, industry leaders can reduce implementation risk, enhance patient access, and sustain commercial viability in an environment characterized by rapid innovation and evolving policy dynamics.

A rigorous mixed-methods research approach combining expert interviews, systematic literature synthesis, and triangulation techniques to underpin strategic conclusions with validated evidence

The research methodology underpinning this analysis integrates primary and secondary approaches designed to ensure rigor, transparency, and reproducibility. Primary research consisted of structured interviews with hematologists, transplant physicians, clinical trial investigators, hospital procurement leaders, and payer representatives to capture firsthand perspectives on clinical practice, procurement constraints, and evidence expectations. Complementing interviews, expert roundtables and advisory consultations provided deeper insight into operational challenges associated with administering transfusions, bone marrow transplants, and emerging gene therapies.

Secondary research involved systematic review of peer-reviewed literature, regulatory documentation, clinical trial registries, and policy publications to triangulate findings and to validate trends observed in primary interactions. Data synthesis emphasized longitudinal evidence where available, and sources were cross-referenced to identify convergent themes related to safety, efficacy, and care delivery. Analytical techniques included qualitative coding of interview transcripts, thematic mapping across segmentation axes, and scenario analysis to explore implications of supply chain and policy shifts.

Limitations of the methodology are acknowledged, including potential variability in regional data availability and the evolving nature of clinical trial outcomes for novel modalities. To mitigate these limitations, the study prioritized high-confidence sources and incorporated sensitivity checks. Quality assurance measures included independent review of analytical outputs and verification of factual statements against primary source material to maintain the integrity of conclusions.

Synthesis of clinical, operational, and policy imperatives that define the pathway to durable patient benefit and sustainable commercialization in sickle cell therapeutics

In conclusion, the trajectory of sickle cell disease treatment is moving from symptom-focused care toward approaches that offer potential disease modification, driven by advances in gene and cell therapies alongside optimized pharmacotherapy and supportive care. This shift presents both opportunities and responsibilities: opportunities to deliver transformative patient outcomes and responsibilities to ensure equitable access, maintain safety oversight, and build the infrastructure required for complex therapy delivery. Strategic success will hinge on the ability of stakeholders to coordinate across clinical, commercial, and policy domains while maintaining patient-centered priorities.

Operational resilience, including manufacturing scale-up and diversified supply chains, is a prerequisite to sustaining access in the face of trade and tariff headwinds. Equally important is the design of robust evidence-generation strategies that address payer concerns and capture long-term patient outcomes. By aligning clinical development with pragmatic implementation planning and by engaging regional stakeholders to address localized barriers, organizations can better translate innovation into meaningful improvements in population health.

Ultimately, the future of sickle cell care depends on collaborative approaches that combine scientific rigor with practical execution. Stakeholders who anticipate operational challenges, prioritize value demonstration, and commit to inclusive access models will be best positioned to deliver durable benefits to patients while achieving commercial and clinical objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sickle Cell Disease Treatment Market, by Treatment Type

  • 8.1. Blood Transfusion
    • 8.1.1. Acute Transfusion
    • 8.1.2. Chronic Transfusion
  • 8.2. Bone Marrow Transplant
    • 8.2.1. Allogeneic Transplant
    • 8.2.2. Autologous Transplant
  • 8.3. Pharmacotherapy
    • 8.3.1. Endari (L-Glutamine) Treatment
    • 8.3.2. Gene Therapy
    • 8.3.3. Hydroxyurea Treatment

9. Sickle Cell Disease Treatment Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Pediatric

10. Sickle Cell Disease Treatment Market, by Drug Administration Method

  • 10.1. Intravenous
  • 10.2. Oral

11. Sickle Cell Disease Treatment Market, by Disease Type

  • 11.1. Hemoglobin SC Disease (HbSC)
  • 11.2. Sickle Cell Anemia (HbSS)

12. Sickle Cell Disease Treatment Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Research Institutions

13. Sickle Cell Disease Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sickle Cell Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sickle Cell Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Sickle Cell Disease Treatment Market

17. China Sickle Cell Disease Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Akums Drugs and Pharmaceuticals Ltd.
  • 18.6. Beam Therapeutics, Inc.
  • 18.7. Biogen Inc.
  • 18.8. Bluebird Bio, Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. CRISPR Therapeutics AG
  • 18.11. Editas Medicine, Inc.
  • 18.12. Emmaus Medical, Inc.
  • 18.13. F. Hoffmann-La Roche AG
  • 18.14. GlycoMimetics, Inc.
  • 18.15. Intellia Therapeutics, Inc.
  • 18.16. Medunik USA
  • 18.17. Novartis AG
  • 18.18. Protagonist Therapeutics, Inc.
  • 18.19. Sangamo Therapeutics, Inc.
  • 18.20. Sanofi S.A.
  • 18.21. Vertex Pharmaceuticals, Inc.
  • 18.22. Vor Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 200. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 210. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)